Automation can take cost out of a prior authorization submission, but what happens after the first rejection determines if it takes cost out of your program entirely.
It’s a fact: electronic prior authorization speeds up the submission. We know that prior authorization is one of the most expensive administrative steps in U.S. healthcare, and electronic prior authorization has proven to make submissions faster. Moving requests off fax and phone cuts staff time, speeds up payer decisions, and costs a fraction of a manual submission. And there’s opportunity for growth: according to the 2025 CAQH Index, the industry still has a $21 billion savings opportunity in administrative transactions that haven't been fully automated.
But the prior authorization process doesn’t stop at the submission. And that’s where the question of whether or not it can ultimately save program costs gets dicey.
ePA doesn't write a letter of medical necessity that answers a specific payer's criteria. It can't decide whether a denial should be appealed or resubmitted with new documentation. It can't prepare a prescriber for a peer-to-peer review, and it can't reconstruct a clinical narrative from records spread across three practices.
In specialty and rare disease programs, those aren't edge cases. Step therapy challenges, weight-based dosing, off-label use, carve-out benefits and the split between the medical and pharmacy benefit are the everyday reality of the caseload. When automation handles the clean requests and passes the rest along without a defined escalation path, the exceptions come back as rework: resubmissions, appeals, and case managers rebuilding a patient's history by hand.
Each of these cases can take several rounds of payer contact before a decision, and none of that work shows up in a dashboard that measures submission time or administrative workload.
Automation is also running on the other side of the transaction. Three-quarters of physicians in the 2025 AMA Prior Authorization Physician Survey say denials have increased over the past five years, and six in 10 are concerned that AI will push denial rates higher still. And faster submissions met with even faster denials don't lower costs.
Lowering the cost of prior authorization means being deliberate about the split: deciding which steps software should own, which need a trained specialist, and how a case moves between the two without sitting in a queue.
How to tell whether automation is lowering your costs
Cost per submission is the wrong KPI. Cost per patient on therapy is the right one. Here's what to look for:
Approval on first submission, tracked separately for each major payer and plan type
Days from prescription to first fill, alongside days from submission to decision
How long it takes to file an appeal after a denial, and how often appeals succeed
Resubmissions per approved case, and how much staff time each one consumes
Patients lost while a request is still pending
Bridge and quick-start utilization, since free drug dispensed during a wait is a direct cost of delay
It also helps to ask how a program handles its hardest cases, not its average ones. Who prepares an appeal, and how quickly? What triggers a handoff from the automated workflow to a specialist? When a request stalls in pended status, how is that noticed, and by whom?
If automation is working, these numbers improve together. If submission speed climbs while time to first fill doesn’t change, the savings are stuck at the front end of the process.
So, can automated prior authorization reduce healthcare costs?
Yes, when it's built to reduce delay and rework. The larger savings come from getting patients approved correctly the first time and onto therapy sooner, which avoids the abandonment, downstream utilization and program spend that prior authorization delays create.
That takes both halves of the model: automation for the predictable work, and experienced specialists for the cases that need judgment. Neither one on its own gets patients to therapy faster or at lower cost.
Automation lowers the cost of prior authorization when it's pointed at the right problem. For specialty programs, that problem isn't how fast a request goes out. It's how quickly a patient gets to first fill.
Want to see where prior authorization is costing your program the most? Talk to the Elusa Health team.
Frequently Asked Questions
Does electronic prior authorization reduce administrative costs?
Yes. Fully electronic transactions cost far less to process than phone, fax or portal submissions, and the 2025 CAQH Index estimates a remaining $21 billion savings opportunity from automating manual and partially manual administrative transactions. Prior authorization is one of the least automated of them, at about 40% fully electronic.
Why doesn't automation alone lower the cost of specialty prior authorization?
Most of the cost sits in delays, denials, appeals and abandonment rather than in the submission itself. Specialty cases are exception-heavy, and exceptions such as step therapy challenges, letters of medical necessity and appeals still require experienced people.
Does the CMS prior authorization rule apply to prescription drugs?
Not yet. CMS-0057-F excludes drugs from its prior authorization provisions. A separate rule proposed in April 2026 (CMS-0062-P) would extend electronic prior authorization requirements to drugs, but it has not been finalized.
What metrics show whether prior authorization automation is working?
First-pass approval rates by payer type, time from prescription to first fill, denial-to-appeal turnaround and overturn rates, rework per case, and abandonment during the prior authorization window.
Sources referenced
Administrative savings opportunity ($21 billion): 2025 CAQH Index announcement, CAQH, February 2026.
Electronic prior authorization adoption (31% to 40%): CAQH Index Finds $20 Billion in Cost Savings Opportunities, AJMC, May 2026.
Physician burden, abandonment, adverse events, utilization and denial trends (40 PAs per week, 13 hours, 79%, 26%, 88%, 74%): 2025 AMA Prior Authorization Physician Survey, American Medical Association, May 2026.
Decision timeframes, denial reasons and API deadline: CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), CMS.
Drug exclusion and CMS-0062-P status: CMS-0057-F Prior Authorization API readiness guide, ChampSoft, August 2026.
